Lymphoid neoplasia: The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1

Blood

Volumn 122, Issue 26, 2013, Pages 4237-4245

  Cader, Fathima Zumla ^a,b   Vockerodt, Martina ^a   Bose, Shikha ^a   Nagy, Eszter ^a   Brundler, Marie Anne ^b   Kearns, Pamela ^a,b   Murray, Paul G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DISCOIDIN DOMAIN RECEPTOR 1; ETOPOSIDE; LATENT MEMBRANE PROTEIN 1; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; DDR1 PROTEIN, HUMAN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA CELL LINE; CELL PROTECTION; CELL SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; GENE SILENCING; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LATENT MEMBRANE ONCOGENE 1; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; LYMPHOMA CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; REED STERNBERG CELL; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; UPREGULATION; VIRUS ONCOGENE; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL CULTURE; CELL DEATH; CYTOLOGY; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL DEATH; CELLS, CULTURED; COLLAGEN; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; GENE KNOCKDOWN TECHNIQUES; GERMINAL CENTER; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; REED-STERNBERG CELLS; TUMOR MICROENVIRONMENT; VIRAL MATRIX PROTEINS;

EID: 84891291773     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-499004     Document Type: Article

References (52)

1. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
2. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010; 221(3):248-263.
3. Provenzano PP, Inman DR, Eliceiri KW, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6:11.
4. Valencia K, Ormaźabal C, Zandueta C, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res. 2012;18(4):969-980.
5. Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J. 2012;441(2):541-552.
6. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177(2):339-349. (Pubitemid 23117083)
7. Murray PG, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol. 1992;166(1):1-5.
8. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337(8737):320-322.
9. Niedobitek G, Kremmer E, Herbst H, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood. 1997;90(4):1664-1672. (Pubitemid 27355441)
10. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood. 1998;92(7):2477-2483. (Pubitemid 28452991)
11. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 1995;10(3):549-560.
12. Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene. 1998;16(13): 1731-1742. (Pubitemid 28175054)
13. Kutz H, Reisbach G, Schultheiss U, Kieser A. The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. Virology. 2008;371(2): 246-256. (Pubitemid 351173227)
14. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 1997; 16(21):6478-6485. (Pubitemid 27483273)
15. Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol. 2007;179(12):8225-8234.
16. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 2000;13(4):497-506.
17. Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16(20):6131-6140. (Pubitemid 27458333)
18. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood. 2005;106(13):4339-4344. (Pubitemid 41775945)
19. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4): 1495-1505. (Pubitemid 26354704)
20. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95(4):1443-1450. (Pubitemid 30099859)
21. Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell. 1997;1(1):13-23. (Pubitemid 127376389)
22. Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal. 2006;18(8): 1108-1116. (Pubitemid 43674043)
23. Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012;31(1-2):295-321.
24. Das S, Ongusaha PP, Yang YS, Park JM, Aaronson SA, Lee SW. Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation. Cancer Res. 2006;66(16): 8123-8130. (Pubitemid 44299179)
25. Ongusaha PP, Kim JI, Fang L, et al. p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J. 2003;22(6):1289-1301. (Pubitemid 36362693)
26. Avivi-Green C, Singal M, Vogel WF. Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2006;174(4):420-427. (Pubitemid 44223123)
27. Ferri N, Carragher NO, Raines EW. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol. 2004;164(5):1575-1585. (Pubitemid 38529760)
28. Guerrot D, Kerroch M, Placier S, et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol. 2011;179(1):83-91.
29. Yang SH, Baek HA, Lee HJ, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep. 2010;24(2):311-319.
30. Barker KT, Martindale JE, Mitchell PJ, et al. Expression patterns of the novel receptor-like tyrosine kinase, DDR, in human breast tumours. Oncogene. 1995;10(3):569-575.
31. Weiner HL, Huang H, Zagzag D, Boyce H, Lichtenbaum R, Ziff EB. Consistent and selective expression of the discoidin domain receptor-1 tyrosine kinase in human brain tumors. Neurosurgery. 2000;47(6):1400-1409.
32. Ram R, Lorente G, Nikolich K, Urfer R, Foehr E, Nagavarapu U. Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and adhesion in association with matrix metalloproteinase-2. J Neurooncol. 2006;76(3): 239-248.
33. Chetoui N, El Azreq MA, Boisvert M, Bergeron ME, Aoudjit F. Discoidin domain receptor 1 expression in activated T cells is regulated by the ERK MAP kinase signaling pathway. J Cell Biochem. 2011;112(12):3666-3674.
34. Kamohara H, Yamashiro S, Galligan C, Yoshimura T. Discoidin domain receptor 1 isoform-a (DDR1alpha) promotes migration of leukocytes in three-dimensional collagen lattices. FASEB J. 2001;15(14):2724-2726.
35. Hachehouche LN, Chetoui N, Aoudjit F. Implication of discoidin domain receptor 1 in T cell migration in three-dimensional collagen. Mol Immunol. 2010;47(9):1866-1869.
36. Vockerodt M, Morgan SL, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol. 2008;216(1):83-92.
37. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA. 2006;12(7):1197-1205. (Pubitemid 43990545)
38. Chen PY, Weinmann L, Gaidatzis D, Pei Y, Zavolan M, Tuschl T, Meister G. Strand-specific 59-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA. 2008;14(2):263-274. (Pubitemid 351171587)
39. Reynolds GM, Billingham LJ, Gray LJ, et al. Interleukin 6 expression by Hodgkin/Reed- Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol. 2002;118(1):195-201. (Pubitemid 34779537)
40. Vrzalikova K, Vockerodt M, Leonard S, et al. Down-regulation of BLIMP1a by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood. 2011;117(22):5907-5917.
41. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA. 2004;101(1):239-244. (Pubitemid 38084234)
42. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1): 75-82. (Pubitemid 33741978)
43. Thorley-Lawson DA, Duca KA, Shapiro M. Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality. Trends Immunol. 2008;29(4):195-201.
44. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13): 1328-1337. (Pubitemid 38375368)
45. Vockerodt M, Wei W, Nagy E, et al. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle. J Pathol. 2013;230(4):399-409.
46. Aldinucci D, Gloghini A, Pinto A, Colombatti A, Carbone A. The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk Lymphoma. 2012;53(2):195-201.
47. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood. 1995;85(3):780-789.
48. Kim LH, Eow GI, Peh SC, Poppema S. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma. Pathology. 2003;35(5):428-435. (Pubitemid 37310985)
49. Rastelli J, Hömig-Hölzel C, Seagal J, Müller W, Hermann AC, Rajewsky K, Zimber-Strobl U. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood. 2008; 111(3):1448-1455. (Pubitemid 351213432)
50. Adler B, Schaadt E, Kempkes B, Zimber-Strobl U, Baier B, Bornkamm GW. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci USA. 2002;99(1):437-442. (Pubitemid 34060379)
51. Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol. 2011;152(3):249-260.
52. Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008;599(1-3):44-53.